P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients

Janielle P. Maynard, Ju Seog Lee, Bo Hwa Sohn, Xiaoying Yu, Dolores Lopez-Terrada, Milton J. Finegold, John A. Goss, Sundararajah Thevananther

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

P2 purinergic receptors are overexpressed in certain cancer tissues, but the pathophysiologic relevance of purinergic signaling in hepatocellular carcinoma (HCC) remains unknown. To examine the role of P2 purinergic signaling in the pathogenesis of HCC and characterize extracellular nucleotide effects on HCC cell proliferation, two independent HCC patient cohorts were analyzed for P2 purinergic receptor expression, and nucleotide treated HCC cell lines were evaluated for effects on proliferation and cell cycle progression. Our studies suggest that multiple P2 purinergic receptor isoforms are overexpressed in liver tumors, as compared to uninvolved liver, and dysregulation of P2 purinergic receptor expression is apparent in HCC cell lines, as compared to human primary hepatocytes. High P2X3 purinergic receptor expression is associated with poor recurrence-free survival (RFS), while high P2Y13 expression is associated with improved RFS. Extracellular nucleotide treatment alone is sufficient to induce cell cycle progression, via activation of JNK signaling, and extracellular ATPmediated activation of P2X3 receptors promotes proliferation in HCC cells. Conclusion: Our analysis of HCC patient livers and HCC cells in vitro identifies a novel role for dysregulation of P2 purinergic signaling in the induction of hyper-proliferative HCC phenotype and identifies P2X3 purinergic receptors as potential new targets for therapy.

Original languageEnglish (US)
Pages (from-to)41162-41179
Number of pages18
JournalOncotarget
Volume6
Issue number38
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Purinergic P2X3 Receptors
Hepatocellular Carcinoma
Recurrence
Survival
Purinergic P2 Receptors
Nucleotides
Liver
Cell Cycle
Cell Line
Hepatocytes
Neoplasms
Protein Isoforms

Keywords

  • Cell-cycle
  • Extracellular ATP
  • Hepatocellular carcinoma
  • JNK signaling
  • Purinergic receptors

ASJC Scopus subject areas

  • Oncology

Cite this

Maynard, J. P., Lee, J. S., Sohn, B. H., Yu, X., Lopez-Terrada, D., Finegold, M. J., ... Thevananther, S. (2015). P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget, 6(38), 41162-41179. https://doi.org/10.18632/oncotarget.6240

P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. / Maynard, Janielle P.; Lee, Ju Seog; Sohn, Bo Hwa; Yu, Xiaoying; Lopez-Terrada, Dolores; Finegold, Milton J.; Goss, John A.; Thevananther, Sundararajah.

In: Oncotarget, Vol. 6, No. 38, 2015, p. 41162-41179.

Research output: Contribution to journalArticle

Maynard, JP, Lee, JS, Sohn, BH, Yu, X, Lopez-Terrada, D, Finegold, MJ, Goss, JA & Thevananther, S 2015, 'P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients', Oncotarget, vol. 6, no. 38, pp. 41162-41179. https://doi.org/10.18632/oncotarget.6240
Maynard, Janielle P. ; Lee, Ju Seog ; Sohn, Bo Hwa ; Yu, Xiaoying ; Lopez-Terrada, Dolores ; Finegold, Milton J. ; Goss, John A. ; Thevananther, Sundararajah. / P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. In: Oncotarget. 2015 ; Vol. 6, No. 38. pp. 41162-41179.
@article{a0513ecedcd14064b63ee6d8b725122f,
title = "P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients",
abstract = "P2 purinergic receptors are overexpressed in certain cancer tissues, but the pathophysiologic relevance of purinergic signaling in hepatocellular carcinoma (HCC) remains unknown. To examine the role of P2 purinergic signaling in the pathogenesis of HCC and characterize extracellular nucleotide effects on HCC cell proliferation, two independent HCC patient cohorts were analyzed for P2 purinergic receptor expression, and nucleotide treated HCC cell lines were evaluated for effects on proliferation and cell cycle progression. Our studies suggest that multiple P2 purinergic receptor isoforms are overexpressed in liver tumors, as compared to uninvolved liver, and dysregulation of P2 purinergic receptor expression is apparent in HCC cell lines, as compared to human primary hepatocytes. High P2X3 purinergic receptor expression is associated with poor recurrence-free survival (RFS), while high P2Y13 expression is associated with improved RFS. Extracellular nucleotide treatment alone is sufficient to induce cell cycle progression, via activation of JNK signaling, and extracellular ATPmediated activation of P2X3 receptors promotes proliferation in HCC cells. Conclusion: Our analysis of HCC patient livers and HCC cells in vitro identifies a novel role for dysregulation of P2 purinergic signaling in the induction of hyper-proliferative HCC phenotype and identifies P2X3 purinergic receptors as potential new targets for therapy.",
keywords = "Cell-cycle, Extracellular ATP, Hepatocellular carcinoma, JNK signaling, Purinergic receptors",
author = "Maynard, {Janielle P.} and Lee, {Ju Seog} and Sohn, {Bo Hwa} and Xiaoying Yu and Dolores Lopez-Terrada and Finegold, {Milton J.} and Goss, {John A.} and Sundararajah Thevananther",
year = "2015",
doi = "10.18632/oncotarget.6240",
language = "English (US)",
volume = "6",
pages = "41162--41179",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "38",

}

TY - JOUR

T1 - P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients

AU - Maynard, Janielle P.

AU - Lee, Ju Seog

AU - Sohn, Bo Hwa

AU - Yu, Xiaoying

AU - Lopez-Terrada, Dolores

AU - Finegold, Milton J.

AU - Goss, John A.

AU - Thevananther, Sundararajah

PY - 2015

Y1 - 2015

N2 - P2 purinergic receptors are overexpressed in certain cancer tissues, but the pathophysiologic relevance of purinergic signaling in hepatocellular carcinoma (HCC) remains unknown. To examine the role of P2 purinergic signaling in the pathogenesis of HCC and characterize extracellular nucleotide effects on HCC cell proliferation, two independent HCC patient cohorts were analyzed for P2 purinergic receptor expression, and nucleotide treated HCC cell lines were evaluated for effects on proliferation and cell cycle progression. Our studies suggest that multiple P2 purinergic receptor isoforms are overexpressed in liver tumors, as compared to uninvolved liver, and dysregulation of P2 purinergic receptor expression is apparent in HCC cell lines, as compared to human primary hepatocytes. High P2X3 purinergic receptor expression is associated with poor recurrence-free survival (RFS), while high P2Y13 expression is associated with improved RFS. Extracellular nucleotide treatment alone is sufficient to induce cell cycle progression, via activation of JNK signaling, and extracellular ATPmediated activation of P2X3 receptors promotes proliferation in HCC cells. Conclusion: Our analysis of HCC patient livers and HCC cells in vitro identifies a novel role for dysregulation of P2 purinergic signaling in the induction of hyper-proliferative HCC phenotype and identifies P2X3 purinergic receptors as potential new targets for therapy.

AB - P2 purinergic receptors are overexpressed in certain cancer tissues, but the pathophysiologic relevance of purinergic signaling in hepatocellular carcinoma (HCC) remains unknown. To examine the role of P2 purinergic signaling in the pathogenesis of HCC and characterize extracellular nucleotide effects on HCC cell proliferation, two independent HCC patient cohorts were analyzed for P2 purinergic receptor expression, and nucleotide treated HCC cell lines were evaluated for effects on proliferation and cell cycle progression. Our studies suggest that multiple P2 purinergic receptor isoforms are overexpressed in liver tumors, as compared to uninvolved liver, and dysregulation of P2 purinergic receptor expression is apparent in HCC cell lines, as compared to human primary hepatocytes. High P2X3 purinergic receptor expression is associated with poor recurrence-free survival (RFS), while high P2Y13 expression is associated with improved RFS. Extracellular nucleotide treatment alone is sufficient to induce cell cycle progression, via activation of JNK signaling, and extracellular ATPmediated activation of P2X3 receptors promotes proliferation in HCC cells. Conclusion: Our analysis of HCC patient livers and HCC cells in vitro identifies a novel role for dysregulation of P2 purinergic signaling in the induction of hyper-proliferative HCC phenotype and identifies P2X3 purinergic receptors as potential new targets for therapy.

KW - Cell-cycle

KW - Extracellular ATP

KW - Hepatocellular carcinoma

KW - JNK signaling

KW - Purinergic receptors

UR - http://www.scopus.com/inward/record.url?scp=84951056714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951056714&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6240

DO - 10.18632/oncotarget.6240

M3 - Article

VL - 6

SP - 41162

EP - 41179

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 38

ER -